175 related articles for article (PubMed ID: 10924924)
1. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
Acquas E; Pisanu A; Marrocu P; Di Chiara G
Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
Gessa GL; Mascia MS; Casu MA; Carta G
Eur J Pharmacol; 1997 May; 327(1):R1-2. PubMed ID: 9185841
[TBL] [Abstract][Full Text] [Related]
4. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
[TBL] [Abstract][Full Text] [Related]
5. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
6. Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.
Acquas E; Pisanu A; Marrocu P; Goldberg SR; Di Chiara G
Eur J Pharmacol; 2001 May; 419(2-3):155-61. PubMed ID: 11426837
[TBL] [Abstract][Full Text] [Related]
7. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
Gifford AN; Samiian L; Gatley SJ; Ashby CR
Eur J Pharmacol; 1997 Apr; 324(2-3):187-92. PubMed ID: 9145770
[TBL] [Abstract][Full Text] [Related]
8. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
9. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
Gifford AN; Ashby CR
J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207
[TBL] [Abstract][Full Text] [Related]
10. Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.
Smith SR; Terminelli C; Denhardt G
Eur J Pharmacol; 2001 Aug; 425(1):73-83. PubMed ID: 11672577
[TBL] [Abstract][Full Text] [Related]
11. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR 141716A.
Vivian JA; Kishioka S; Butelman ER; Broadbear J; Lee KO; Woods JH
J Pharmacol Exp Ther; 1998 Aug; 286(2):697-703. PubMed ID: 9694923
[TBL] [Abstract][Full Text] [Related]
12. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
Ihenetu K; Molleman A; Parsons M; Whelan C
Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
[TBL] [Abstract][Full Text] [Related]
14. Large receptor reserve for cannabinoid actions in the central nervous system.
Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
[TBL] [Abstract][Full Text] [Related]
15. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Landi M; Croci T; Rinaldi-Carmona M; Maffrand JP; Le Fur G; Manara L
Eur J Pharmacol; 2002 Aug; 450(1):77-83. PubMed ID: 12176112
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid modulation of intestinal propulsion in mice.
Colombo G; Agabio R; Lobina C; Reali R; Gessa GL
Eur J Pharmacol; 1998 Feb; 344(1):67-9. PubMed ID: 9570450
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of SR141716A on G-protein activation in rat brain.
Sim-Selley LJ; Brunk LK; Selley DE
Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
[TBL] [Abstract][Full Text] [Related]
18. Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice.
Smith SR; Terminelli C; Denhardt G
J Pharmacol Exp Ther; 2000 Apr; 293(1):136-50. PubMed ID: 10734163
[TBL] [Abstract][Full Text] [Related]
19. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat.
Verrico CD; Jentsch JD; Dazzi L; Roth RH
Synapse; 2003 Jun; 48(4):178-83. PubMed ID: 12687636
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]